Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 66

1.

Omega-3 Fatty Acid-Derived Resolvin D2 Regulates Human Placental Vascular Smooth Muscle and Extravillous Trophoblast Activities.

Ulu A, Sahoo PK, Yuil-Valdes AG, Mukherjee M, Van Ormer M, Muthuraj PG, Thompson M, Anderson Berry A, Hanson CK, Natarajan SK, Nordgren TM.

Int J Mol Sci. 2019 Sep 7;20(18). pii: E4402. doi: 10.3390/ijms20184402.

2.

Prophylactic inhibition of soluble epoxide hydrolase delays onset of nephritis and ameliorates kidney damage in NZB/W F1 mice.

Klocke J, Ulu A, Wu K, Rudolph B, Dragun D, Gollasch M, Schunck WH, Hammock BD, Riemekasten G, Enghard P.

Sci Rep. 2019 Jun 20;9(1):8993. doi: 10.1038/s41598-019-45299-5.

3.

Investigation of toxic effects of amorphous SiO2 nanoparticles on motility and oxidative stress markers in rainbow trout sperm cells.

Özgür ME, Ulu A, Özcan İ, Balcioglu S, Ateş B, Köytepe S.

Environ Sci Pollut Res Int. 2019 May;26(15):15641-15652. doi: 10.1007/s11356-019-04941-5. Epub 2019 Apr 4.

PMID:
30949942
4.

Regulation of Somatostatin Receptor 2 Trafficking by C-Tail Motifs and the Retromer.

Olsen C, Memarzadeh K, Ulu A, Carr HS, Bean AJ, Frost JA.

Endocrinology. 2019 May 1;160(5):1031-1043. doi: 10.1210/en.2018-00865.

PMID:
30822353
5.

The Toxicity Assessment of Iron Oxide (Fe₃O₄) Nanoparticles on Physical and Biochemical Quality of Rainbow Trout Spermatozoon.

Özgür ME, Ulu A, Balcıoğlu S, Özcan İ, Köytepe S, Ateş B.

Toxics. 2018 Oct 18;6(4). pii: E62. doi: 10.3390/toxics6040062.

6.

Regulation of RhoA activation and cell motility by c-Jun N-terminal kinases and Net1.

Ulu A, Frost JA.

Small GTPases. 2018 Oct 17:1-7. doi: 10.1080/21541248.2018.1536638. [Epub ahead of print]

PMID:
30332929
7.

The Causes of Postoperative Meningitis: The Comparison of Gram-Negative and Gram-Positive Pathogens.

Kurtaran B, Kuscu F, Ulu A, Inal AS, Komur S, Kibar F, Cetinalp NE, Ozsoy KM, Arslan YK, Yilmaz DM, Aksu H, Tasova Y.

Turk Neurosurg. 2018;28(4):589-596. doi: 10.5137/1019-5149.JTN.20575-17.1.

8.

Chloro-Modified Magnetic Fe3O4@MCM-41 Core-Shell Nanoparticles for L-Asparaginase Immobilization with Improved Catalytic Activity, Reusability, and Storage Stability.

Ulu A, Noma SAA, Koytepe S, Ates B.

Appl Biochem Biotechnol. 2019 Mar;187(3):938-956. doi: 10.1007/s12010-018-2853-9. Epub 2018 Aug 13.

PMID:
30101367
9.

Tigecycline in the treatment of multidrug-resistant Acinetobacter baumannii meningitis: Results of the Ege study.

Sipahi OR, Mermer S, Demirdal T, Ulu AC, Fillatre P, Ozcem SB, Kaya Ş, Şener A, Bulut C, Tekin R, Kahraman H, Özgiray E, Yurtseven T, Sipahi H, Arda B, Pullukçu H, Taşbakan M, Yamazhan T, Aydemir S, Ulusoy S.

Clin Neurol Neurosurg. 2018 Sep;172:31-38. doi: 10.1016/j.clineuro.2018.06.008. Epub 2018 Jun 10.

10.

Potential Drug-Drug Interactions with Antimicrobials in Hospitalized Patients: A Multicenter Point-Prevalence Study.

Kuscu F, Ulu A, Inal AS, Suntur BM, Aydemir H, Gul S, Ecemis K, Komur S, Kurtaran B, Ozkan Kuscu O, Tasova Y.

Med Sci Monit. 2018 Jun 20;24:4240-4247. doi: 10.12659/MSM.908589.

11.

The in vitro toxicity analysis of titanium dioxide (TiO2) nanoparticles on kinematics and biochemical quality of rainbow trout sperm cells.

Özgür ME, Balcıoğlu S, Ulu A, Özcan İ, Okumuş F, Köytepe S, Ateş B.

Environ Toxicol Pharmacol. 2018 Sep;62:11-19. doi: 10.1016/j.etap.2018.06.002. Epub 2018 Jun 12.

PMID:
29913268
12.

Magnetic Fe3O4@MCM-41 core-shell nanoparticles functionalized with thiol silane for efficient l-asparaginase immobilization.

Ulu A, Noma SAA, Koytepe S, Ates B.

Artif Cells Nanomed Biotechnol. 2018;46(sup2):1035-1045. doi: 10.1080/21691401.2018.1478422. Epub 2018 Jun 6.

PMID:
29873527
13.

Contributions of the RhoA guanine nucleotide exchange factor Net1 to polyoma middle T antigen-mediated mammary gland tumorigenesis and metastasis.

Zuo Y, Ulu A, Chang JT, Frost JA.

Breast Cancer Res. 2018 May 16;20(1):41. doi: 10.1186/s13058-018-0966-2.

14.

Design of epoxy-functionalized Fe3O4@MCM-41 core-shell nanoparticles for enzyme immobilization.

Ulu A, Ozcan I, Koytepe S, Ates B.

Int J Biol Macromol. 2018 Aug;115:1122-1130. doi: 10.1016/j.ijbiomac.2018.04.157. Epub 2018 May 1.

PMID:
29727644
15.

Correction to Optimized Inhibitors of Soluble Epoxide Hydrolase Improve in Vitro Target Residence Time and in Vivo Efficacy.

Lee KSS, Liu JY, Wagner KM, Pakhomova S, Dong H, Morisseau C, Fu SH, Yang J, Wang P, Ulu A, Mate CA, Nguyen LV, Hwang SH, Edin ML, Mara AA, Wulff H, Newcomer ME, Zeldin DC, Hammock BD.

J Med Chem. 2018 May 10;61(9):4271. doi: 10.1021/acs.jmedchem.8b00582. Epub 2018 Apr 27. No abstract available.

16.

Stress-activated MAPKs and CRM1 regulate the subcellular localization of Net1A to control cell motility and invasion.

Ulu A, Oh W, Zuo Y, Frost JA.

J Cell Sci. 2018 Feb 1;131(3). pii: jcs204644. doi: 10.1242/jcs.204644.

17.

Furuncular Myiasis Caused by Dermatobia hominis in a Traveler Returning from the Amazon Jungle.

Kuşcu F, Özsoy KM, Ulu A, Kurtaran B, Kömür S, İnal AS, Taşova Y, Aksu HSZ.

Turkiye Parazitol Derg. 2017 Sep;41(3):173-176. doi: 10.5152/tpd.2017.4927.

18.

The Causes of Post-Operative Meningitis: The Comparison Of Gram-Negative and Gram-Positive Pathogens.

Kurtaran B, Kuscu F, Ulu A, Inal AS, Komur S, Kibar F, Cetinalp NE, Ozsoy KM, Arslan YK, Aksu HS, Tasova Y.

Turk Neurosurg. 2017 Jun 20. doi: 10.5137/1019-5149.JTN.20575-17.1. [Epub ahead of print]

19.

Rickettsia sibirica mongolitimonae Infection, Turkey, 2016.

Kuscu F, Orkun O, Ulu A, Kurtaran B, Komur S, Inal AS, Erdogan D, Tasova Y, Aksu HSZ.

Emerg Infect Dis. 2017 Jul;23(7):1214-1216. doi: 10.3201/eid2307.170188.

20.

Immobilization of l-Asparaginase on Carrier Materials: A Comprehensive Review.

Ulu A, Ates B.

Bioconjug Chem. 2017 Jun 21;28(6):1598-1610. doi: 10.1021/acs.bioconjchem.7b00217. Epub 2017 May 30. Review.

PMID:
28505420
21.

Inhibition of soluble epoxide hydrolase as a novel approach to high dose diazepam induced hypotension.

Ulu A, Inceoglu B, Yang J, Singh V, Vito S, Wulff H, Hammock BD.

J Clin Toxicol. 2016 Jun;6(3). pii: 1000300. doi: 10.4172/2161-0495.1000300. Epub 2016 May 30.

22.

Design of starch functionalized biodegradable P(MAA-co-MMA) as carrier matrix for l-asparaginase immobilization.

Ulu A, Koytepe S, Ates B.

Carbohydr Polym. 2016 Nov 20;153:559-572. doi: 10.1016/j.carbpol.2016.08.019. Epub 2016 Aug 6.

PMID:
27561529
23.

Mucormycosis: a 10-year experience at a tertiary care center in Turkey.

Kömür S, İnal AS, Kurtaran B, Ulu A, Uğuz A, Aksu HS, Taşova Y.

Turk J Med Sci. 2016 Jan 5;46(1):58-62. doi: 10.3906/sag-1409-137.

PMID:
27511334
24.

Regulation of RhoA activation and cytoskeletal organization by acetylation.

Ulu A, Frost JA.

Small GTPases. 2016 Apr 2;7(2):76-81. doi: 10.1080/21541248.2016.1171283. Epub 2016 Apr 12.

25.

Addition of DHA Synergistically Enhances the Efficacy of Regorafenib for Kidney Cancer Therapy.

Kim J, Ulu A, Wan D, Yang J, Hammock BD, Weiss RH.

Mol Cancer Ther. 2016 May;15(5):890-8. doi: 10.1158/1535-7163.MCT-15-0847. Epub 2016 Feb 26.

26.

Minireview: Mouse Models of Rho GTPase Function in Mammary Gland Development, Tumorigenesis, and Metastasis.

Zuo Y, Oh W, Ulu A, Frost JA.

Mol Endocrinol. 2016 Mar;30(3):278-89. doi: 10.1210/me.2015-1294. Epub 2015 Dec 17. Review.

27.

Telaprevir experience from Turkey.

Komur S, Kurtaran B, Inal AS, Pullukcu H, Ulu A, Kuscu F, Yamazhan T, Tasova Y, Aksu HS.

Hepat Mon. 2015 Feb 18;15(2):e25639. doi: 10.5812/hepatmon.25639. eCollection 2015 Feb.

28.

Effects of mannose-binding lectin and mannose-binding lectin polymorphisms on treatment response in patients with chronic hepatitis C.

Kömür S, İnal AS, Ulu AC, Kurtaran B, Taşova Y, Salih H, Aksu Z.

Turk J Gastroenterol. 2014 Dec;25(6):702-6. doi: 10.5152/tjg.2014.6583.

29.

Acetylation of the RhoA GEF Net1A controls its subcellular localization and activity.

Song EH, Oh W, Ulu A, Carr HS, Zuo Y, Frost JA.

J Cell Sci. 2015 Mar 1;128(5):913-22. doi: 10.1242/jcs.158121. Epub 2015 Jan 14.

30.

Biomarkers in IgA nephropathy.

Hwang VJ, Ulu A, van Hoorebeke J, Weiss RH.

Biomark Med. 2014;8(10):1263-77. doi: 10.2217/bmm.14.92. Review.

PMID:
25525986
31.

Aberrant soluble epoxide hydrolase and oxylipin levels in a porcine arteriovenous graft stenosis model.

Terry CM, Carlson ML, He Y, Ulu A, Morisseau C, Blumenthal DK, Hammock BD, Cheung AK.

J Vasc Res. 2014;51(4):269-82. doi: 10.1159/000365251. Epub 2014 Sep 5.

32.

Optimized inhibitors of soluble epoxide hydrolase improve in vitro target residence time and in vivo efficacy.

Lee KS, Liu JY, Wagner KM, Pakhomova S, Dong H, Morisseau C, Fu SH, Yang J, Wang P, Ulu A, Mate CA, Nguyen LV, Hwang SH, Edin ML, Mara AA, Wulff H, Newcomer ME, Zeldin DC, Hammock BD.

J Med Chem. 2014 Aug 28;57(16):7016-30. doi: 10.1021/jm500694p. Epub 2014 Aug 11. Erratum in: J Med Chem. 2018 May 10;61(9):4271.

33.

An omega-3 epoxide of docosahexaenoic acid lowers blood pressure in angiotensin-II-dependent hypertension.

Ulu A, Stephen Lee KS, Miyabe C, Yang J, Hammock BG, Dong H, Hammock BD.

J Cardiovasc Pharmacol. 2014 Jul;64(1):87-99. doi: 10.1097/FJC.0000000000000094.

34.

Role of KIR genes and genotypes in susceptibility to or protection against hepatitis B virus infection in a Turkish cohort.

Kibar F, Goruroglu Ozturk O, Ulu A, Erken E, Inal S, Dinkci S, Kurtaran B, Tasova Y, Aksu HS, Yaman A.

Med Sci Monit. 2014 Jan 10;20:28-34. doi: 10.12659/MSM.889893.

35.

Anti-inflammatory effects of ω-3 polyunsaturated fatty acids and soluble epoxide hydrolase inhibitors in angiotensin-II-dependent hypertension.

Ulu A, Harris TR, Morisseau C, Miyabe C, Inoue H, Schuster G, Dong H, Iosif AM, Liu JY, Weiss RH, Chiamvimonvat N, Imig JD, Hammock BD.

J Cardiovasc Pharmacol. 2013 Sep;62(3):285-97. doi: 10.1097/FJC.0b013e318298e460.

36.

Epoxy metabolites of docosahexaenoic acid (DHA) inhibit angiogenesis, tumor growth, and metastasis.

Zhang G, Panigrahy D, Mahakian LM, Yang J, Liu JY, Stephen Lee KS, Wettersten HI, Ulu A, Hu X, Tam S, Hwang SH, Ingham ES, Kieran MW, Weiss RH, Ferrara KW, Hammock BD.

Proc Natl Acad Sci U S A. 2013 Apr 16;110(16):6530-5. doi: 10.1073/pnas.1304321110. Epub 2013 Apr 3.

37.

Use of a soluble epoxide hydrolase inhibitor as an adjunctive analgesic in a horse with laminitis.

Guedes AG, Morisseau C, Sole A, Soares JH, Ulu A, Dong H, Hammock BD.

Vet Anaesth Analg. 2013 Jul;40(4):440-8. doi: 10.1111/vaa.12030. Epub 2013 Mar 7.

38.

Role of soluble epoxide hydrolase phosphatase activity in the metabolism of lysophosphatidic acids.

Morisseau C, Schebb NH, Dong H, Ulu A, Aronov PA, Hammock BD.

Biochem Biophys Res Commun. 2012 Mar 23;419(4):796-800. doi: 10.1016/j.bbrc.2012.02.108. Epub 2012 Feb 24.

39.

Pharmacokinetics and in vivo potency of soluble epoxide hydrolase inhibitors in cynomolgus monkeys.

Ulu A, Appt S, Morisseau C, Hwang SH, Jones PD, Rose TE, Dong H, Lango J, Yang J, Tsai HJ, Miyabe C, Fortenbach C, Adams MR, Hammock BD.

Br J Pharmacol. 2012 Mar;165(5):1401-12. doi: 10.1111/j.1476-5381.2011.01641.x.

40.

Inhibition of soluble epoxide hydrolase contributes to the anti-inflammatory effect of antimicrobial triclocarban in a murine model.

Liu JY, Qiu H, Morisseau C, Hwang SH, Tsai HJ, Ulu A, Chiamvimonvat N, Hammock BD.

Toxicol Appl Pharmacol. 2011 Sep 1;255(2):200-6. doi: 10.1016/j.taap.2011.06.017. Epub 2011 Jun 25.

41.

Analgesia mediated by soluble epoxide hydrolase inhibitors is dependent on cAMP.

Inceoglu B, Wagner K, Schebb NH, Morisseau C, Jinks SL, Ulu A, Hegedus C, Rose T, Brosnan R, Hammock BD.

Proc Natl Acad Sci U S A. 2011 Mar 22;108(12):5093-7. doi: 10.1073/pnas.1101073108. Epub 2011 Mar 7.

42.

Soluble epoxide hydrolase in the generation and maintenance of high blood pressure in spontaneously hypertensive rats.

Koeners MP, Wesseling S, Ulu A, Sepúlveda RL, Morisseau C, Braam B, Hammock BD, Joles JA.

Am J Physiol Endocrinol Metab. 2011 Apr;300(4):E691-8. doi: 10.1152/ajpendo.00710.2010. Epub 2011 Jan 25.

43.

Soluble epoxide hydrolase in atherosclerosis.

Wang YX, Ulu A, Zhang LN, Hammock B.

Curr Atheroscler Rep. 2010 May;12(3):174-83. doi: 10.1007/s11883-010-0108-5. Review.

44.

Inhibition of soluble epoxide hydrolase enhances the anti-inflammatory effects of aspirin and 5-lipoxygenase activation protein inhibitor in a murine model.

Liu JY, Yang J, Inceoglu B, Qiu H, Ulu A, Hwang SH, Chiamvimonvat N, Hammock BD.

Biochem Pharmacol. 2010 Mar 15;79(6):880-7. doi: 10.1016/j.bcp.2009.10.025. Epub 2009 Nov 5.

45.

Characteristics of cutaneous anthrax in Turkey.

Baykam N, Ergonul O, Ulu A, Eren S, Celikbas A, Eroglu M, Dokuzoguz B.

J Infect Dev Ctries. 2009 Sep 15;3(8):599-603.

46.

Soluble epoxide hydrolase and epoxyeicosatrienoic acids modulate two distinct analgesic pathways.

Inceoglu B, Jinks SL, Ulu A, Hegedus CM, Georgi K, Schmelzer KR, Wagner K, Jones PD, Morisseau C, Hammock BD.

Proc Natl Acad Sci U S A. 2008 Dec 2;105(48):18901-6. doi: 10.1073/pnas.0809765105. Epub 2008 Nov 21.

47.

Soluble epoxide hydrolase inhibitors reduce the development of atherosclerosis in apolipoprotein e-knockout mouse model.

Ulu A, Davis BB, Tsai HJ, Kim IH, Morisseau C, Inceoglu B, Fiehn O, Hammock BD, Weiss RH.

J Cardiovasc Pharmacol. 2008 Oct;52(4):314-23. doi: 10.1097/FJC.0b013e318185fa3c.

48.

The correlation between soluble endothelial protein c receptor (sEPCR) and tumor necrosis factor-alpha (TNF-α) levels in vivo.

Ulu A, Egin Y, Akar N.

Turk J Haematol. 2008 Jun 5;25(2):108-9. No abstract available.

PMID:
27264452
49.

The importance of thrombotic risk factors in the development of idiopathic sudden hearing loss.

Yildiz Z, Ulu A, Incesulu A, Ozkaptan Y, Akar N.

Clin Appl Thromb Hemost. 2008 Jul;14(3):356-9. Epub 2007 Dec 26.

PMID:
18160602
50.

The role of plasminogen activator inhibitor-1 polymorphism, factor-V-Leiden, and prothrombin-20210 mutations in pulmonary thromboembolism.

Oguzulgen IK, Yilmaz E, Demirtas S, Erkekol FO, Ekim N, Demir N, Numanoglu N, Ozel D, Ulu A, Akar N.

Clin Appl Thromb Hemost. 2009 Feb;15(1):73-7. Epub 2007 Dec 26. Erratum in: Clin Appl Thromb Hemost. 2009 May-Jun;15(3):367. Yilmaz, E [added].

PMID:
18160588

Supplemental Content

Support Center